Travere Therapeutics Q1 2025 10-Q Filed
Ticker: TVTX · Form: 10-Q · Filed: May 1, 2025 · CIK: 1438533
| Field | Detail |
|---|---|
| Company | Travere Therapeutics, Inc. (TVTX) |
| Form Type | 10-Q |
| Filed Date | May 1, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
TL;DR
Travere Therapeutics Q1 2025 10-Q is in. Financials for product sales and licenses detailed.
AI Summary
Travere Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance, including revenue from product sales and licenses for the first quarter of 2025 and 2024. Key financial data points such as common stock, additional paid-in capital, and retained earnings as of December 31, 2024, and 2023 are also presented.
Why It Matters
This filing provides investors with the latest financial snapshot of Travere Therapeutics, crucial for understanding the company's performance and financial health in early 2025.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Travere Therapeutics faces inherent risks related to drug development, clinical trials, regulatory approvals, and market competition.
Key Numbers
- 2025-03-31 — Period End Date (Latest reported quarter)
- 2025-01-01 — Period Start Date (Latest reported quarter)
- 2024-12-31 — Previous Year End Date (Balance sheet comparison)
- 2023-12-31 — Prior Year End Date (Balance sheet comparison)
Key Players & Entities
- Travere Therapeutics, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — Period of report
- 20250501 (date) — Filing date
- Retrophin, Inc. (company) — Former company name
- Desert Gateway, Inc. (company) — Former company name
FAQ
What were Travere Therapeutics's product and license revenues for the first quarter of 2025?
The filing indicates revenue from product sales and licenses for the period January 1, 2025, to March 31, 2025, but specific dollar amounts are not detailed in the provided snippet.
What is the company's SIC code?
The Standard Industrial Classification (SIC) code for Travere Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
When did Travere Therapeutics change its name from Retrophin, Inc.?
The company changed its name from Retrophin, Inc. on February 20, 2013.
What is the company's principal business address?
The principal business address is 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA 92130.
What is the fiscal year end for Travere Therapeutics?
The fiscal year end for Travere Therapeutics is December 31.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 1, 2025 regarding Travere Therapeutics, Inc. (TVTX).